Imagine you had a compact, portable device that could deliver critical healthcare insights directly into the hands of the people who need them most. A simple, versatile solution that could test for a wide range of diseases and provide results within minutes, whether in a primary care clinic, pharmacy, or hospital. That was the vision on which the LumiraDx platform was built, with the aim of transforming healthcare at the point of care.
It’s a vision that aligns perfectly with our own. At the forefront of innovation in point of care diagnostics for over four decades, Roche has long-standing experience delivering solutions that enable faster, more reliable testing and diagnosis close to the patient. And now, recognising the potential of LumiraDx’s technology and expertise to further accelerate innovation in near-patient care, that vision is bringing the two companies together to fully integrate LumiraDx’s platform, capabilities and network into the wider Roche family.
LumiraDx was founded in 2014 with a bold mission: to transform community-based healthcare by bringing advanced diagnostics directly to the point of care. Their flagship product, launched just five years later, is a testament to this vision. Weighing only 1.1kg, and powered by rechargeable battery or mains, the instrument is a portable platform capable of delivering testing for infectious diseases, cardiovascular disease, diabetes and coagulation disorders on a single device. It offers accurate results in minutes at the point of care, and a means of addressing some of the biggest challenges in healthcare, including diagnostic availability in resource-limited countries and rural settings.
LumiraDx's diagnostic testing solutions are being deployed globally across laboratories, urgent care, physician offices, and community settings to help screen, diagnose, and monitor wellness as well as disease.
As health systems around the world grapple with the increasing costs of an older population in poorer health, diagnostic solutions that help clinicians manage, monitor and prevent diseases are more important than ever. Enabling a shift from treating sickness to caring for health, diagnostic tools that give accurate and timely results reduce the strain on healthcare systems by facilitating early intervention and targeted treatment plans.
Decentralised care is also a critical opportunity for cost containment. Shifting testing and diagnostic capabilities closer to patients, such as in clinics or pharmacies, reduces reliance on specialist, central laboratories, and enhances efficiency by accelerating the process. This not only saves time but also lowers the operational costs associated with sending samples to off-site testing facilities.
It’s also a way of ensuring that more patients can access the high quality testing that underpins accurate healthcare decision-making. With many people around the world, particularly in low- and middle-income countries, lacking access to reliable diagnostics due to limited healthcare infrastructure, decentralising care becomes a crucial step towards closing this gap. By bringing testing closer to where patients live, including remote and underserved communities, decentralised diagnostics have the potential to democratise healthcare, ensuring more equitable access to essential medical services globally.
LumiraDx’s technology platform becoming part of the Roche family goes far beyond the instrument and tests themselves. With entrepreneurial roots and a single-minded focus on point of care testing, it is ideally positioned to accelerate progress in this area. Bringing a wealth of skills, and innovative R&D and manufacturing approaches, the team is set to enhance Roche’s collective expertise and drive forward new solutions in diagnostics.
Together with new colleagues from LumiraDx, Roche aims to build on the technology and to continue exploring other potential targets for the platform, further expanding its capabilities with new tests to address a wider array of diseases. By pushing the boundaries of what point of care diagnostics can achieve, Roche hopes to make advanced, rapid testing accessible to even more patients, ultimately enhancing outcomes and setting a new standard in healthcare delivery worldwide.
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.